Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 122

Similar articles for PubMed (Select 23912172)

1.

Pretransplantation GAD-autoantibody status to guide prophylactic antibody induction therapy in simultaneous pancreas and kidney transplantation.

Ringers J, van der Torren CR, van de Linde P, van der Boog PJ, Mallat MJ, Bonifacio E, Roep BO, de Fijter JW.

Transplantation. 2013 Oct 27;96(8):745-52. doi: 10.1097/TP.0b013e3182a012cc.

PMID:
23912172
2.

Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients.

Huurman VA, Kalpoe JS, van de Linde P, Vaessen N, Ringers J, Kroes AC, Roep BO, De Fijter JW.

Diabetes Care. 2006 Apr;29(4):842-7.

PMID:
16567825
4.

Randomized comparison of triple therapy and antithymocyte globulin induction treatment after simultaneous pancreas-kidney transplantation.

Cantarovich D, Karam G, Giral-Classe M, Hourmant M, Dantal J, Blancho G, Le Normand L, Soulillou JP.

Kidney Int. 1998 Oct;54(4):1351-6.

5.

Selective unresponsiveness to beta cell autoantigens after induction immunosuppression in pancreas transplantation with anti-interleukin-2 receptor antibody versus anti-thymocyte globulin.

van de Linde P, Vd Boog PJ, Tysma OM, Elliott JF, Roelen DL, Claas FH, de Fijter JW, Roep BO.

Clin Exp Immunol. 2007 Jul;149(1):56-62. Epub 2007 Apr 25.

6.
7.

Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation.

Pilch NA, Taber DJ, Moussa O, Thomas B, Denmark S, Meadows HB, McGillicuddy JW, Srinivas TR, Baliga PK, Chavin KD.

Ann Surg. 2014 May;259(5):888-93. doi: 10.1097/SLA.0000000000000496.

PMID:
24513787
8.
9.

A comparison of daclizumab to ATGAM induction in simultaneous pancreas-kidney transplant recipients on triple maintenance immunosuppression.

Rasaiah SB, Light JA, Sasaki TM, Currier CB.

Clin Transplant. 2000 Aug;14(4 Pt 2):409-12.

PMID:
10946780
10.

Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection.

Sollinger H, Kaplan B, Pescovitz MD, Philosophe B, Roza A, Brayman K, Somberg K.

Transplantation. 2001 Dec 27;72(12):1915-9.

PMID:
11773888
11.

Single-shot antithymocyte globulin (ATG) induction for pancreas/kidney transplantation: ATG-Fresenius versus Thymoglobulin.

Schulz T, Papapostolou G, Schenker P, Kapischke M.

Transplant Proc. 2005 Mar;37(2):1301-4.

PMID:
15848703
12.

A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients.

Charpentier B, Rostaing L, Berthoux F, Lang P, Civati G, Touraine JL, Squifflet JP, Vialtel P, Abramowicz D, Mourad G, Wolf P, Cassuto E, Moulin B, Rifle G, Pruna A, Merville P, Mignon F, Legendre C, Le Pogamp P, Lebranchu Y, Toupance O, Hurault De Ligny B, Touchard G, Olmer M, Purgus R, Pouteil-Noble C, Glotz D, Bourbigot B, Leski M, Wauters JP, Kessler M.

Transplantation. 2003 Mar 27;75(6):844-51.

PMID:
12660513
13.

Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.

Lü TM, Yang SL, Wu WZ, Tan JM.

Chin Med J (Engl). 2011 Mar;124(5):664-8.

PMID:
21518554
14.

Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.

Nashan B, Light S, Hardie IR, Lin A, Johnson JR.

Transplantation. 1999 Jan 15;67(1):110-5.

PMID:
9921806
15.

Induction therapy after cardiac transplantation: a comparison of anti-thymocyte globulin and daclizumab in the prevention of acute rejection.

Carlsen J, Johansen M, Boesgaard S, Andersen CB, Arendrup H, Aldershvilet J, Mortensen SA.

J Heart Lung Transplant. 2005 Mar;24(3):296-302.

PMID:
15737756
16.

Effects of induction immunosuppression regimen on acute rejection, bronchiolitis obliterans, and survival after lung transplantation.

Ailawadi G, Smith PW, Oka T, Wang H, Kozower BD, Daniel TM, Kron IL, Jones DR.

J Thorac Cardiovasc Surg. 2008 Mar;135(3):594-602. doi: 10.1016/j.jtcvs.2007.10.044. Epub 2008 Jan 18.

PMID:
18329476
18.

The efficacy and safety of alemtuzumab and daclizumab versus antithymocyte globulin during organ transplantation: a meta-analysis.

Hao WJ, Zong HT, Cui YS, Zhang Y.

Transplant Proc. 2012 Dec;44(10):2955-60. doi: 10.1016/j.transproceed.2012.05.085. Review.

PMID:
23195005
19.

Randomized trial of dual antibody induction therapy with steroid avoidance in renal transplantation.

Ciancio G, Gaynor JJ, Sageshima J, Guerra G, Zarak A, Roth D, Brown R, Kupin W, Chen L, Hanson L, Tueros L, Ruiz P, Livingstone AS, Burke GW 3rd.

Transplantation. 2011 Dec 27;92(12):1348-57. doi: 10.1097/TP.0b013e3182384b21.

PMID:
22027927
20.

Effect of prophylaxis with low-dose anti-thymocyte globulin on prevention of acute kidney allograft rejection.

Khosroshahi HT, Tubbs RS, Shoja MM, Ghafari A, Noshad H, Ardalan MR.

Transplant Proc. 2008 Jan-Feb;40(1):137-9. doi: 10.1016/j.transproceed.2007.12.016.

PMID:
18261569
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk